Three different isoforms of trypsinogen have been described in human pancreatic secretions. According to their electrophoretic mobility on isoelectric focusing, they have been designated as cationic trypsinogen (PRSS1), anionic trypsinogen (PRSS2) and mesotrypsinogen (PRSS3) 3 . Anionic trypsinogen, also referred to as serine protease 2, is one of the most abundant secretory proteins synthesized by the pancreas 3, 4 . The ratio of the anionic to the cationic forms is approximately 1:2, whereas mesotrypsinogen is secreted only in low quantities 3 . Compared with the cationic isoenzyme, anionic trypsinogen autoactivates less easily, particularly at acidic pH, and is more sensitive to autolysis 5, 6 . The gene encoding human PRSS2 (OMIM 601564) maps to 7q35, is approximately 3.6 kb long and contains five exons 7 . The preproprotein comprises 247 amino acids, including a 15-residue signal peptide and an eight-residue activation peptide.
Mutations in PRSS1 (OMIM 276000) and SPINK1 (OMIM 167790) are strongly associated with hereditary and idiopathic chronic pancreatitis 1, 2 . However, the majority of affected individuals do not carry mutations in either of these two genes, suggesting that defects in further genes might be involved in the pathogenesis of the disease 2 . Because mutations in PRSS1 can cause pancreatitis, we hypothesized that, by analogy, gene variants of the anionic isoenzyme PRSS2 could also modify the susceptibility to chronic pancreatitis. We therefore investigated the coding regions and flanking intronic sequences of PRSS2 in 200 German affected individuals and 240 controls by SSCP analysis and direct DNA sequencing.
In these subjects, we identified three missense PRSS2 variants. Two of the variants, T8I and V118I, were equally common among individuals with chronic pancreatitis (12.5% and 5%, respectively) and controls (15% and 4.6%, respectively). In contrast, the third variant, a G-A transition resulting in a substitution of glycine by arginine at codon 191 in exon 4 (G191R), was present in 9/240 (3.8%) control subjects but not in any of the 200 affected individuals investigated.
We subsequently expanded the study to include additional German affected individuals and controls. Using melting curve analysis, we confirmed the higher prevalence of the heterozygous G191R variant in the control group (71/2,019 (3.5%)) versus individuals with chronic pancreatitis (19/1,548 (1.2%)) (odds ratio (OR) 0.34; P ¼ 0.000012) ( Table 1) .
In order to investigate whether our findings were applicable to other European populations, we investigated an additional 918 individuals with chronic pancreatitis and 4,440 control subjects from Austria, the Czech Republic, Denmark, France, Italy, the Netherlands, Romania, Spain and Switzerland. Because of the low case numbers in some of these populations, we pooled them together as a European sample without Germans. The frequency (3.4%) and 95% confidence interval (c.i.) (2.8-3.9) for the controls in this European sample lay well in the range of the German sample (frequency ¼ 3.5%; 95% c.i. ¼ 2.7-4.3). The frequency in controls (149/4,440 (3.4%)) was significantly higher than in individuals with chronic pancreatitis (13/918 (1.4%)) (OR 0.41; P ¼ 0.00097) ( Table 1) . Taking all sampled European populations together, the frequency of G191R was 1.3% (32/2,466) in the group of affected individuals, compared with 3.4% (220/6,459) among control subjects (OR ¼ 0.37; P ¼ 1.1 Â 10 À8 ) ( Table 1) . Stratification of the subgroups (alcoholic pancreatitis and idiopathic/hereditary pancreatitis) showed no significant differences between the different groups of affected individuals. For detailed data, see Supplementary  Table 1 online.
Further analyses showed that affected individuals with the G191R variant were of higher age than those without the protective variant. In the idiopathic/hereditary pancreatitis group, we found G191R in 24/1,256 (1.9%) affected individuals older than 20 years compared with 3/601 (0.5%) affected individuals aged 20 years or younger (P ¼ 0.021); however, owing to limited sample size, these data should be interpreted with caution. A similar tendency was observed in the alcoholic chronic pancreatitis group: none of the 162 affected individuals aged 40 years or younger had the G191R variant, compared with 5/447 (1.1%) of affected individuals older than 40 years (P ¼ 0.332; Supplementary Table 1) . No age-related differences were observed in the control group (3.4% in individuals aged 20 years or younger versus 3.3% in those over 20 years; 3.2% in individuals aged 40 years or younger versus 3.5% in individuals over 40 years).
In contrast to unaffected Europeans, who showed a G191R frequency of 3.4%, the variant was rare in individuals of African descent (2/948), with an estimated overall frequency of 0.2% (95% c.i. ¼ 0-0.5), which was significantly different from the frequency we found in the European population (P ¼ 10 À11 ).
One of the 6,459 control subjects (originating from the Netherlands), but none of the affected individuals, was homozygous for G191R. When analyzing the G191R variation among 204 parents of Austrian or German individuals with chronic pancreatitis, we detected six G191R carriers. However, the variant was not transmitted from the unaffected parent to the affected child in any of the cases.
To exclude that G191R is in linkage disequilibrium (LD) with other variants in PRSS2 or PRSS1, which is located only 40 kb centromeric to PRSS2, we bidirectionally sequenced the complete PRSS1 and PRSS2 coding sequence in 60 PRSS2 G191R heterozygotes (ten affected individuals and 50 controls). With exception of the common PRSS2 polymorphisms T8I and V118I, which were present in a similar frequency as found in the above-mentioned German affected individuals and control subjects (15% and 1.7%, respectively), we did not find any other PRSS2 variant within the coding region. Moreover, none of these 60 G191R heterozygotes carried a PRSS1 missense mutation.
In order to determine the haplotype structure in the genomic context of G191R, we analyzed 17 SNPs (going from rs2156965 to rs985180) around PRSS2 (Fig. 1) . From a cohort of 95 subjects corresponding to 36 families with at least a carrier of G191R, we found a small common haplotype always associated with G191R (233112 or CGGAAC in Table 2a ; Block 1 in Fig. 1 ). This minimum haplotype starts at rs10273639 (located within PRSS1 40 kb centromeric from PRSS2) and ends with rs2367487 (located 15 kb telomeric from PRSS2) corresponding to an interval of B60 kb (D ¢ ¼ 0.90). In contrast, we found eight different haplotypes on 72 chromosomes bearing wild-type PRSS2 (Table 2a) . Taking into account a SNP 51 kb centromeric from PRSS2 (rs1964986) and 22 kb telomeric from PRSS2 (rs2071361), we found three haplotypes: we found the first haplotype on 10/22 chromosomes (46%), the second on 8/22 chromosomes (36%) and the third on 4/22 chromosomes (18%) ( Table 2b) .
We then aimed to exclude the genetic effect of potential causative variant(s) in any non-233112 haplotypes. In all German affected individuals and control subjects, we further analyzed rs10273639, which tags the two most common haplotypes (233312 and 411314), and rs997222, which tags the only other haplotype with a significant frequency (233342; 10%) ( Table 2a) . Allele frequencies of both SNPs did not significantly differ between affected individuals and controls: rs10273639 T was present in 1,277/3,096 (41.2%) affected individuals versus 1,715/4,038 (42.5%) controls (P ¼ 0.31), and rs997222 T was present in 242/3,096 (7.8%) affected individuals versus 355/4,038 (8.8%) controls (P ¼ 0.14). In addition, haplotype analysis as well as the very rare frequency of G191R in individuals of African descent indicate that G191R is a founder allele and not a recurrent mutation.
The glycine at position 191 is strictly conserved in vertebrate trypsinogens. Although the crystal structure of human anionic trypsin remains to be solved, comparison with rat trypsin or the homologous human cationic trypsin (PRSS1) structure (Fig. 2) suggests that Gly191 is located on the surface of the enzyme near the primary substrate binding pocket. Therefore, the G191R alteration is expected to generate a surface-exposed, positively charged, bulky arginine side chain. This Arg191-Gly192 peptide bond would be predicted to be highly amenable to cleavage by trypsin. PRSS2 lacks the conserved Cys139-Cys206 disulfide bond that would prevent the dissociation of the C-terminal proteolytic fragment 8 . This fragment contains the catalytic Ser200 residue, which is essential for enzymatic activity (Fig. 2) . The cleavage should, therefore, inactivate trypsin(ogen) rapidly and irreversibly.
To test this hypothesis, we recombinantly expressed wild-type anionic trypsinogen and the G191R variant. Both the physiological activator enteropeptidase (enterokinase) and trypsin strongly activated wild-type PRSS2, and the trypsin activity generated remained stable over the entire time period studied. In contrast, the G191R variant showed only minimal or no tryptic activity after activation (Fig. 3) . Analysis of the activation process by reducing SDS-PAGE showed a time-dependent conversion of trypsinogen to trypsin for wild-type PRSS2. In contrast, activation of the G191R variant led to a strong new band corresponding to the N-terminal proteolytic fragment of trypsinogen cleaved after Arg191 (Fig. 3a-c) . Removal of the activation peptide from this proteolytic fragment by enteropeptidase yielded a smaller fragment corresponding to the N-terminal fragment of trypsin cleaved after Arg191 (Fig. 3a) . We further characterized the proteolytic processing of the G191R mutant by mass spectrometry (Fig. 4) (Fig. 4) . Incubation with trypsin as activating enzyme similarly demonstrated rapid cleavage of the G191R mutant at the Arg191-Gly192 peptide bond (data not shown). Taken together, this functional analysis confirms that the G191R substitution generates a supersensitive tryptic cleavage site and destines anionic trypsin(ogen) for autocatalytic degradation. It is currently thought that pancreatitis results from an imbalance of proteases and their inhibitors within the pancreatic parenchyma. It has been shown that a gain-of-function mutation in the cationic trypsinogen gene is a cause of hereditary pancreatitis 1 . A more recent study provided evidence that loss-of-function mutations in the specific trypsin inhibitor, SPINK1, can also predispose to chronic pancreatitis 2 . Thus, it is now generally believed that inappropriate intrapancreatic activation of trypsinogen is a precondition for acinar cell injury and pancreatitis. Along the same line of thought, it is conceivable that lossof-function trypsinogen mutations should afford protection against pancreatitis. The present study is the first to experimentally support this notion not only by identifying a previously unknown PRSS2 variant that is significantly underrepresented in individuals with pancreatitis from various geographic regions but also by providing experimental evidence that this variant conveys a loss of function. Although the overall contribution of G191R to disease pathogenesis is low, the functional characterization of the G191R variant reported here provides the first example in pancreatitis-and a rare example as far as inheritable diseases in general are concerned-for a diseaseprotective genetic variant.
METHODS
Individuals affected with chronic pancreatitis. This study was approved by the medical ethical review committee of the Charité University Hospital. All affected individuals gave informed consent for genetic analysis. The study population included 2,466 individuals suffering from chronic pancreatitis (609 with alcohol-related disease and 1,857 with either idiopathic or hereditary etiology) originating from Austria (n ¼ 24), the Czech Republic (n ¼ 92), France (n ¼ 359), Germany (n ¼ 1,548), Italy (n ¼ 141), the Netherlands (n ¼ 139), Romania (n ¼ 3), Spain (n ¼ 64) and Switzerland (n ¼ 96). The clinical diagnosis of chronic pancreatitis was based on two or more of the file 1TRN) showing Gly191 (chymotrypsin numbering (chymo#) Gly187) mutated to Arg (in red). Also shown is the primary specificity determinant Asp194 (in green; chymo#Asp189) and the catalytic triad His63, Asp107 and Ser200 (in orange, chymo# His57, Asp102 and Ser195). The yellow peptide segment is removed after cleavage of the Arg191-Gly192 peptide bond. Activation assays and gel electrophoresis were carried out as described in Methods. Trypsin activity was expressed as percentage of the potential total activity. In experiments b and c, the activity of the added trypsin was subtracted from the total activity measured. The single asterisk indicates the N-terminal trypsinogen fragment generated by cleavage of the Arg191-Gly192 peptide bond. This trypsinogen fragment was further processed by enteropeptidase to the corresponding trypsin fragment (**). The C-terminal peptide was not detected under these electrophoretic conditions. Control experiments using human pancreatic trypsin inhibitor demonstrate that enteropeptidase cannot cleave the Arg191-Gly192 peptide bond and that the degradation observed during enteropeptidase activation is entirely attributable to trypsin (data not shown).
following criteria: presence of a typical history of recurrent pancreatitis, radiological findings such as pancreatic calcifications and/or pancreatic ductal irregularities revealed by endoscopic retrograde pancreatography or by magnetic resonance imaging of the pancreas and/or pathological sonographic findings. Hereditary chronic pancreatitis was diagnosed when two first-degree relatives or three or more second-degree relatives suffered from recurrent acute or chronic pancreatitis without any apparent precipitating factor. Affected individuals were classified as having idiopathic chronic pancreatitis when precipitating factors, such as alcohol abuse, trauma, medication, infection, metabolic disorders and/or a positive family history, were absent. Alcoholinduced chronic pancreatitis was diagnosed in affected individuals who consumed more than 60 g (females) or 80 g (males) of ethanol per day for more than two years. The 6,459 control subjects were recruited from Austria (n ¼ 637), the Czech Republic (n ¼ 522), Denmark (n ¼ 95), France (n ¼ 1,120), Germany (n ¼ 2,019), Italy (n ¼ 326), the Netherlands (n ¼ 565), Romania (n ¼ 163), Spain (n ¼ 518) and Switzerland (n ¼ 494).
To determine the frequency of G191R in non Europeans, we studied 948 individuals of African descent originating from Benin (n ¼ 161), Cameroon (n ¼ 412), Ethiopia (n ¼ 155), and Ecuador (n ¼ 220). Detailed characteristics of affected individuals are available online as Supplementary Table 2 online.
Mutation screening. Oligonucleotide sequences and PCR conditions for PRSS2 are available online as Supplementary Methods. Sequencing of PRSS1 was performed as described previously 9 . We analyzed DNA by sequencing both strands of the entire coding region.
Melting curve analysis. We performed melting curve analysis to detect the G191R variant using a pair of fluorescence resonance energy transfer (FRET) probes and the LightCycler (Roche Diagnostics). The sensor probe was 5¢-CAGGAATCCTTGCCTCCCTC-FL-3¢ (FL: 5,6-carboxyfluorescein attached to 3¢-O-ribose) and the anchor probe was 5¢-LC-AGGAAGCCCACACAGAA CATGTTGTTG-ph-3¢ (LC: LightCycler Red 640 attached to 5¢ terminus; ph: 3¢ phosphate). The sensor probe was complementary to the wild-type sequence resulting in an allele-specific melting curve (62.5 1C versus 56 1C). For further details on melting curve analysis and assay validation see the Supplementary Methods available online.
Haplotype analysis. For haplotype analysis we selected a total of 17 SNPs (going from rs2156965, located 117 kb centromeric from PRSS2, to rs985180, located 63 kb telomeric from PRSS2; Fig. 1 ) from HapMap. We determined the genotypes of 95 subjects from 36 families with at least a carrier of G191R by direct DNA sequencing. In five cases, we were unable to determine the haplotype. Oligonucleotide sequences and PCR conditions for amplifying the five SNPs defining Block 1 (rs10273639, rs1985888, rs2855983, rs997222, rs2367487) as well as the two nearest SNPs flanking Block 1 (rs1964986 and rs2071361) are available online in Supplementary Methods. Pairwise LD was calculated and visualized using the Haploview program 10 .
Mutation modeling. We modeled the effect of the G191R variant using the human cationic trypsin crystal structure 11 . The image was rendered using DeepView/Swiss-PdbViewer (v. 3.7) 12 .
Generation of recombinant PRSS2 and activation assays. Site-directed mutagenesis, recombinant expression, in vitro refolding and purification of human trypsinogens were carried out as described previously 13, 14 . Recombinant trypsinogen preparations (2 mM final concentration) were incubated at 37 1C, in 0.1 M Tris-HCl (pH 8.0) and 1 mM CaCl 2 , in a final volume of 100 ml. Activation was initiated with 20 ng/ml bovine enteropeptidase (Biozyme) or 0.1 mM trypsin (final concentrations). Aliquots of 2.5 ml were withdrawn from reaction mixtures at indicated times, and trypsin activity was determined with 0.14 mM (final concentration) N-CBZ-GlyPro-Arg-p-nitroanilide. Activity was expressed as percentage of the potential total activity, which was determined on a separate wild-type trypsinogen sample after activation with enteropeptidase at 22 1C in 0.1 M Tris-HCl (pH 8.0) and 10 mM Ca 2+ . For electrophoretic gel analysis, samples were precipitated with 10% trichloroacetic acid (final concentration), resolved by 12% SDS-PAGE under reducing conditions and stained with Coomassie blue, as described earlier 15 .
Mass spectrometric determination of cleavage sites. Identification of the cleavage sites within Arg191 trypsinogen was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Wild-type and Arg191 trypsinogens were incubated in 10 ml of 50 mM ammonium bicarbonate buffer, pH 8.0, containing 10 mM CaCl 2 and 10 milliunits enteropeptidase (Sigma). At the indicated time points, 0.5-ml aliquots were taken and subsequently cocrystallized with 0.5 ml sinapinic acid (saturated in 70% acetonitrile) on a SCOUT 384 -MALDI-Target. Mass spectrometry was performed on a MALDI-TOF-MS (Reflex III, Bruker Daltonics) instrument in linear mode with internal calibration. Annotation of trypsinogen fragments was performed with BioTools 2.0 software (Bruker Daltonics).
Statistics. The significance of the differences between mutation frequencies in affected individuals and controls as well as between different control populations were tested by two-tailed Fisher's Exact tests, and additional odds ratios were calculated using SAS/STAT software (v 9.1). Figure 4 Mass spectrometric analysis of trypsinogen activation. Wild-type and Arg191 variant anionic trypsinogen were incubated at pH 8.0 in the presence of 10 mM CaCl 2 , as described in Methods. At the indicated time points, samples were withdrawn and directly analyzed by MALDI-TOF mass spectrometry. The left shoulders observed on the trypsinogen peaks are due to partial N-terminal processing of recombinant trypsinogen by Escherichia coli aminopeptidases; the right shoulders are sinapinic acid adducts. The molecular masses indicated correspond to average peptide masses with cysteines oxidized as disulfides. Note that recombinant trypsinogens contain an extra methionine at the N terminus.
